4700-56-5 Usage
General Description
(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-benzo-1,4-diazepin-3-yl) hydrogen succinate is a chemical compound that belongs to the class of benzodiazepines, which are psychoactive drugs that act as central nervous system depressants. The compound consists of a benzodiazepine core with a chlorine atom and a phenyl group, as well as a succinate group attached to the core. Benzodiazepines are commonly used as sedatives, hypnotics, and anxiolytics and are known for their ability to enhance the effects of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-benzo-1,4-diazepin-3-yl) hydrogen succinate's specific structure and properties make it potentially useful for pharmaceutical purposes, such as in the development of new medications to treat conditions such as anxiety, insomnia, and seizures.
Check Digit Verification of cas no
The CAS Registry Mumber 4700-56-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,7,0 and 0 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 4700-56:
(6*4)+(5*7)+(4*0)+(3*0)+(2*5)+(1*6)=75
75 % 10 = 5
So 4700-56-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H15ClN2O5/c20-12-6-7-14-13(10-12)17(11-4-2-1-3-5-11)22-19(18(26)21-14)27-16(25)9-8-15(23)24/h1-7,10,19H,8-9H2,(H,21,26)(H,23,24)
4700-56-5Relevant articles and documents
Oxazepam-Dopamine Conjugates Increase Dopamine Delivery into Striatum of Intact Rats
Cassano, Tommaso,Lopalco, Antonio,De Candia, Modesto,Laquintana, Valentino,Lopedota, Angela,Cutrignelli, Annalisa,Perrone, Mara,Iacobazzi, Rosa M.,Bedse, Gaurav,Franco, Massimo,Denora, Nunzio,Altomare, Cosimo D.
, p. 3178 - 3187 (2017/09/11)
The neurotransmitter dopamine (DA) was covalently linked to oxazepam (OXA), a well-known positive allosteric modulator of γ-aminobutyric acid type-A (GABAA) receptor, through a carbamate linkage (4) or a succinic spacer (6). These conjugates were synthesized with the aim of improving the delivery of DA into the brain and enhancing GABAergic transmission, which may be useful for the long-term treatment of Parkinson disease (PD). Structure-based permeability properties, in vitro stability, and blood-brain barrier (BBB) permeability studies led to identify the OXA-DA carbamate conjugate 4a as the compound better combining sufficient stability and ability to cross BBB. Finally, in vivo microdialysis experiments in freely moving rats demonstrated that 4a (20 mg/kg, i.p.) significantly increases extracellular DA levels into striatum, with a peak (more than 15-fold increase over the baseline) at about 80 min after a single administration. The stability and delivery data proved that 4a may be a promising candidate for further pharmacological studies in animal models of PD.
